Population Pharmacokinetic Modelling of Irosustat in Postmenopausal Women with Oestrogen-Receptor Positive Breast Cancer Incorporating Non-Linear Red Blood Cell Uptake

被引:0
作者
Zinnia P. Parra-Guillen
Josep María Cendrós Carreras
Concepción Peraire
Rosendo Obach
Joan Prunynosa
Eric Chetaille
Iñaki F. Trocóniz
机构
[1] University of Navarra,Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy
[2] University of Barcelona,Pharmacy and Pharmaceutical Technology Department
[3] Ipsen Innovation,undefined
来源
Pharmaceutical Research | 2015年 / 32卷
关键词
anticancer drugs; non-linear pharmacokinetics; NONMEM; population pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1493 / 1504
页数:11
相关论文
共 125 条
[11]  
Brusco L(2000)Elevated steroid sulfatase expression in breast cancers J Steroid Biochem Mol Biol 73 141-5
[12]  
Fuqua SAW(2003)Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma Cancer Res 63 2762-70
[13]  
Geisler J(2000)In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE Cancer Res 60 3394-6
[14]  
Reed MJ(2006)In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy Clin Cancer Res 12 5543-9
[15]  
Purohit A(2011)In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification Drug Metab Dispos 39 1235-46
[16]  
Woo LWL(2012)In vitro evaluation of the interaction potential of irosustat with drug-metabolizing enzymes Drug Metab Dispos 40 1268-78
[17]  
Newman SP(2013)A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer Breast Cancer Res Treat 140 73-82
[18]  
Potter BVL(2004)Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats Br J Cancer 91 1399-404
[19]  
Dowsett M(1993)The importance of modeling interoccasion variability in population pharmacokinetic analyses J Pharmacokinet Biopharm 21 735-50
[20]  
Goss P(1994)Comparison of the Akaike information criterion, the Schwarz criterion and the F test as guides to model selection J Pharmacokinet Pharmacodyn 22 431-45